2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2021
End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis
Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Supportive Care In Cancer 2021, 29: 3921-3932. PMID: 33389087, DOI: 10.1007/s00520-020-05964-2.Peer-Reviewed Original ResearchConceptsCancer-directed therapySymptom management servicesLung cancerMedicare beneficiariesCare contentYounger ageEarlier hospice enrollmentLife care patternsLung cancer decedentsPercentage of patientsClaims-based analysisMethodsThis retrospective studyMost Medicare beneficiariesNonhospice settingsCancer decedentsUsual careHospice enrollmentSymptom managementRetrospective studyMedicare databaseSkilled nursingHigh comorbidityCare intensityMedicare claimsMultinomial logistic regression